Compare NPO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPO | SRRK |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.8B |
| IPO Year | 2002 | 2018 |
| Metric | NPO | SRRK |
|---|---|---|
| Price | $289.67 | $46.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $278.33 | $56.17 |
| AVG Volume (30 Days) | 124.0K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $1,532,000,000.00 | N/A |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $6.39 | $534.24 |
| P/E Ratio | $112.51 | ★ N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $202.00 | $27.07 |
| 52 Week High | $390.42 | $61.76 |
| Indicator | NPO | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 30.44 |
| Support Level | $259.63 | $45.81 |
| Resistance Level | $303.49 | $48.23 |
| Average True Range (ATR) | 9.72 | 2.65 |
| MACD | -0.10 | -1.24 |
| Stochastic Oscillator | 30.10 | 4.87 |
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through two segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies, which manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.